A novel drug delivery system using IL-2 activated NK cells and Zyn-Linked doxorubicin

In Vivo

Volumn 14, Issue 1, 2000, Pages 101-104

  Goldfarb, Ronald H ^a,d   Koelemij, Ronald ^c   Muirhead, Katharine A ^f   Ohlsson Wilhelm, Betsy M ^f   Gray, Brian D ^e   Kuppen, Peter J K ^c   Basse, Per H ^b   Al Atrash, Gheath ^a,d   Kitson, Richard P ^a,d  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SciGro   (United States)

^e PTI Research Inc   (United States)

^f Univ N Texas Hlth Sci Ctr F ^*

Author keywords

Doxorubicin; Drug delivery; NK cells

Indexed keywords

DOXORUBICIN; DYE; UNCLASSIFIED DRUG; ZYN 205; ZYN LINKERS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG LABELING; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA B16; MEMBRANE BINDING; MOUSE; NATURAL KILLER CELL; NONHUMAN; TUMOR CELL LINE; TUMOR LOCALIZATION;

EID: 0034031140     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 474-488, 1991.
2. Basse PH, Goldfarb RH: Localization of immune effector cells to tumor metastases. In: Tumor Immunology and Cancer Therapy (Goldfarh RH, Whiteside TL, eds). New York, Marcel Dekker, Inc., 1994, pp 149-158.
3. Kitson RP, Baker MA, Muirhead KA, Ohlsson-Wilhelm BM, Seth K, Gray B, Rao V, Basse PH, Goldfarb RH: A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. Proc Am Assoc Can Res 37: 301, 1996.
4. Goldfarb RH, Kitson RP, Brunson KW: Biology of cancer metastases. In: Regional Therapy of Advanced Cancer (Lotze MT, Rubin JT, eds). Philadelphia, Lippincott-Raven, 1996, pp 1-9.
5. Zanovello P, Rosato A, Bronte V, Cerundolo V, Collavo D: Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins. Annali dell Istituto Superiore di Sanita 27: 91-5, 1991.
6. Mandruzzato S, Rosato A, Bronte V, Zanovello P, Amboldi N, Ballinari D, Collavo D: Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice hearing lung metastases. Cancer Res 54: 1016-20, 1994.
7. Quintieri L, Rosato A, Amboldi N, Vizler C, Ballinari D, Zanovello P, Collavo D: Delivery of methoxymorpholinyl doxoruhicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases. Br J Cancer 79: 1067-73, 1999.
8. Ohlsson-Wilhelm BM, McDevitt MR, Gray BD, Lorinc R, McIlvain HB, Sheth K, Weeks SA, Muirhead KA: Zyn-Linker delivery of antirheumatic agents. Immunol Res 13: 82-95, 1994.
9. Baker MA, Ohlsson-Wihelm BA, Satyaswaroop PG, Lorinc R, Carpenter DC, Gray BD, Yu Z, Burns JF, Muirhead KA: Conjugation of therapeutics to lipophilic molecules, Zyn-Linkers, enhances in vivo efficacy. J Cont Rel 40: 89-100, 1996.
10. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E: Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 142: 1748-1754, 1989.
11. Sheth KA, Baker MA, Ohlsson-Wilhelm BM, Satyaswaroop PG, Carpenter DC, Lorinc R, Miller SA, Gray BD, Muirhead KA: Zyn-linking doxorubicin reduces toxicity and retains efficacy against local and metastatic tumor models. Proc Amer Assoc Cancer Res 36: 307, 1995.
12. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278-83, 1979.